Oxford, UK – 09 November 2020. OGT, A Sysmex Group Company, will be hosting a live workshop at the upcoming Association for Molecular Pathology (AMP) 2020 virtual meeting, in which users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations. The workshop, Implementing SureSeq Myeloid and CLL Panels for comprehensive genomic profiling of haematological malignancies, will be held on Wednesday 18th November at 4:30 PM EST.
During the workshop, Tracy Tucker, PhD, FCCMG, Cytogeneticist and Molecular Geneticist, Cancer Genetics and Genomics, BC Cancer Agency, and Associate Professor, University of British Columbia, will be talking about transitioning CLL FISH analysis into the molecular biomarker era using OGT’s SureSeq CLL + CNV panel. Her presentation will be followed by Elizabeth McCready, PhD, FCCMG, Head of Molecular Cytogenetics, Hamilton Regional Laboratory Medicine Program, and Associate Professor, McMaster University, who will compare a hybridization-based NGS panel versus single analyte and amplicon-based NGS assays for somatic mutation testing in myeloid malignancies, from her experience with OGT’s SureSeq myPanel Custom Myeloid - 49 gene plus panel.
OGT’s NGS panels offer unparalleled coverage uniformity to detect low-frequency SNVs and indels consistently and with confidence. The SureSeq CLL + CNV panel can detect CNVs ranging from single exons to full chromosome arms and trisomies, which allows the profiling of samples for CNVs in the five most commonly aberrated regions in CLL. By replacing multiple assays with a single NGS panel, the SureSeq CLL + CNV panel can increase throughput and reduce turnaround time. OGT’s SureSeq myPanel Custom Myeloid - 49 gene plus panel offers robust detection of difficult to sequence genes such as CEBPA variants, FLT3-ITDs and KMT2A-PTDs, ensuring comprehensive aberration detection in a highly streamlined workflow. OGT’s customers are able to accurately identify a comprehensive range of variants and CNVs using the company’s complimentary, powerful, and easy-to-use Interpret analysis software.
“The AMP virtual meeting is a great opportunity to showcase the exceptional data quality of our NGS panels, and we’re pleased that Drs Tucker and McCready are able to share their research with delegates”, said OGT’s CEO, John Anson. “OGT is fully committed to the NGS space. We offer robust NGS panels that target the most relevant content and various types of aberrations - including CNV detection - and a complete range of NGS consumables, all backed up by the renowned expertise of our technical specialists. Being part of Sysmex, a large, global IVD company, has opened up a number of exciting possibilities for OGT, and we have many exciting plans for developing and expanding our NGS offering.”
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
For more information on the Company, please visit our website at ogt.com
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
New content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.Read
Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.Read